Literature DB >> 17596432

Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.

Alfonso García-Piñeres1, Allan Hildesheim, Lori Dodd, Troy J Kemp, Marcus Williams, Clayton Harro, Douglas R Lowy, John T Schiller, Ligia A Pinto.   

Abstract

To determine the systemic cytokine pattern induced by vaccination with human papillomavirus (HPV) L1 virus-like particles (VLP), we analyzed 22 different cytokines in culture supernatants of L1 VLP-stimulated peripheral blood mononuclear cells from vaccine (n = 19) and placebo (n = 7) recipients at months 0 and 2 after vaccination, using a multiplex cytokine bead array. In vaccine recipients, incubation with L1 VLP in vitro led to a statistically significant increase in production of Th1 (granulocyte-macrophage colony-stimulating factor, interleukin-2 [IL-2], gamma interferon; P < 0.0007) and Th2 (IL-4, IL-5, IL-10, IL-13; P < 0.0017) cytokines and the chemokine IP-10 (P = 0.0021) at month 2 after immunization, compared to levels seen prior to vaccination. These responses were not seen in placebo recipients. Cytokine and neutralizing antibody responses to vaccination followed the same pattern, with the highest antibody responses seen for subjects with higher cytokine responses. Cytokine profiling studies using samples from efficacy trials may provide important information about discriminators of long-term protection against HPV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17596432      PMCID: PMC2044489          DOI: 10.1128/CVI.00090-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  29 in total

Review 1.  Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression.

Authors:  I Julkunen; T Sareneva; J Pirhonen; T Ronni; K Melén; S Matikainen
Journal:  Cytokine Growth Factor Rev       Date:  2001 Jun-Sep       Impact factor: 7.638

2.  A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.

Authors:  T G Evans; W Bonnez; R C Rose; S Koenig; L Demeter; J A Suzich; D O'Brien; M Campbell; W I White; J Balsley; R C Reichman
Journal:  J Infect Dis       Date:  2001-04-24       Impact factor: 5.226

Review 3.  Defense against influenza A virus infection: essential role of the chemokine system.

Authors:  A Kaufmann; R Salentin; R G Meyer; D Bussfeld; C Pauligk; H Fesq; P Hofmann; M Nain; D Gemsa; H Sprenger
Journal:  Immunobiology       Date:  2001-12       Impact factor: 3.144

4.  Papillomavirus-like particles induce acute activation of dendritic cells.

Authors:  P Lenz; P M Day; Y Y Pang; S A Frye; P N Jensen; D R Lowy; J T Schiller
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

5.  Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells.

Authors:  Petra Lenz; Cynthia D Thompson; Patricia M Day; Silvia M Bacot; Douglas R Lowy; John T Schiller
Journal:  Clin Immunol       Date:  2003-03       Impact factor: 3.969

6.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

Authors:  C D Harro; Y Y Pang; R B Roden; A Hildesheim; Z Wang; M J Reynolds; T C Mast; R Robinson; B R Murphy; R A Karron; J Dillner; J T Schiller; D R Lowy
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

7.  Activation of IFN-alpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells.

Authors:  T Ronni; T Sareneva; J Pirhonen; I Julkunen
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

8.  Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.

Authors:  Darron R Brown; Kenneth H Fife; Cosette M Wheeler; Laura A Koutsky; Lisa M Lupinacci; Radha Railkar; Gretchen Suhr; Eliav Barr; Anthony Dicello; Weili Li; Judith F Smith; Amha Tadesse; Kathrin U Jansen
Journal:  Vaccine       Date:  2004-07-29       Impact factor: 3.641

9.  A controlled trial of a human papillomavirus type 16 vaccine.

Authors:  Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Eliav Barr; Frances B Alvarez; Lisa M Chiacchierini; Kathrin U Jansen
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

10.  Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine.

Authors:  Rebecca T Emeny; Cosette M Wheeler; Kathrin U Jansen; William C Hunt; Tong-Ming Fu; Judith F Smith; Stefani MacMullen; Mark T Esser; Xavier Paliard
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more
  20 in total

1.  Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response.

Authors:  Rossella Talotta; Angela Berzi; Fabiola Atzeni; Alberto Batticciotto; Mario Clerici; Piercarlo Sarzi-Puttini; Daria Trabattoni
Journal:  J Clin Immunol       Date:  2015-08-14       Impact factor: 8.317

2.  Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles.

Authors:  Fatma M Shebl; Ligia A Pinto; Alfonso García-Piñeres; Richard Lempicki; Marcus Williams; Clayton Harro; Allan Hildesheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

3.  Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.

Authors:  Douglas M Herrin; Emily E Coates; Pamela J Costner; Troy J Kemp; Martha C Nason; Kapil K Saharia; Yuanji Pan; Uzma N Sarwar; Lasonji Holman; Galina Yamshchikov; Richard A Koup; Yuk Ying S Pang; Robert A Seder; John T Schiller; Barney S Graham; Ligia A Pinto; Julie E Ledgerwood
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.

Authors:  Yinin Hu; Mark E Smolkin; Emily J White; Gina R Petroni; Patrice Y Neese; Craig L Slingluff
Journal:  Ann Surg Oncol       Date:  2014-05-20       Impact factor: 5.344

5.  Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice.

Authors:  Zahra Kianmehr; Hoorieh Soleimanjahi; Susan Kaboudanian Ardestani; Fatemeh Fotouhi; Asghar Abdoli
Journal:  Med Microbiol Immunol       Date:  2014-09-04       Impact factor: 3.402

6.  Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.

Authors:  Tilo Senger; Lysann Schädlich; Sonja Textor; Corinna Klein; Kristina M Michael; Christopher B Buck; Lutz Gissmann
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

7.  Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining.

Authors:  Steven G Smith; Maeve K Lalor; Patricia Gorak-Stolinska; Rose Blitz; Natalie E R Beveridge; Andrew Worth; Helen McShane; Hazel M Dockrell
Journal:  BMC Immunol       Date:  2010-07-07       Impact factor: 3.615

8.  Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model.

Authors:  Daniel W Sepkovic; Johann Stein; Antoine D Carlisle; H Barbara Ksieski; Karen Auborn; H Leon Bradlow
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

9.  Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus.

Authors:  Hae-Mi Nam; Kyung-Sil Chae; Young-Jo Song; Nak-Hyung Lee; Joong-Bok Lee; Seung-Yong Park; Chang-Seon Song; Kun-Ho Seo; Sang-Moo Kang; Min-Chul Kim; In-Soo Choi
Journal:  Arch Virol       Date:  2013-02-08       Impact factor: 2.574

10.  Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles.

Authors:  L Buonaguro; M L Tornesello; R C Gallo; Franco M Marincola; G K Lewis; F M Buonaguro
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.